Helsinn welcomes anamorelin trials publication in Lancet Oncology

23 February 2016

Swiss cancer care specialist Helsinn has welcomed the publication of positive data from anamorelin ROMANA 1 and ROMANA 2 Phase III studies in the Lancet Oncology.

The studies showed anamorelin significantly improved lean body mass, body weight and symptom burden including appetite in non-small cell lung cancer (NSCLC) patients with cancer anorexia-cachexia.

Cancer anorexia-cachexia is a common condition in patients with advanced cancer and in particular in those with lung cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK